Viking's Earnings Call: More Than Numbers, A Pipeline Under Scrutiny

SAN DIEGO, CA – February 05, 2026 – Viking Therapeutics is set to report its fourth-quarter and full-year 2025 financial results next week, but for investors and industry observers, the numbers on the balance sheet may take a backseat to the narrative. The clinical-stage biopharmaceutical company has scheduled a conference call for after the market closes on February 11, an event that is widely anticipated not for its earnings figures—which are expected to reflect continued heavy investment in research—but for critical updates on its high-stakes pipeline in the blockbuster obesity and liver disease markets.

As Viking navigates the final stages of development for its most promising drug candidates, the upcoming call will serve as a crucial barometer for its progress, strategic direction, and ability to compete with pharmaceutical giants.

Beyond the Balance Sheet: Pipeline Progress is Paramount

While financial reports are a routine part of corporate life, for a clinical-stage company like Viking, the true value lies in its science. The conference call will provide a platform for management to elaborate on the progress of its key clinical programs, and analysts will be listening intently for any new details or shifts in timelines.

The spotlight will undoubtedly be on VK2735, Viking's dual GLP-1/GIP agonist for obesity. The company is advancing both an injectable and an oral formulation, a strategy that could offer a competitive edge. The subcutaneous version is already in a Phase 3 registration program, VANQUISH, with enrollment for the first of two trials, VANQUISH-1, completed in November 2025. Investors will be eager for updates on the enrollment progress of the second trial, VANQUISH-2, and any commentary on the path to a potential regulatory submission.

Equally important will be the discussion around the oral formulation of VK2735. The drug delivered impressive weight-loss results in a Phase 2 study last year, showing a placebo-adjusted reduction of 10.9% over 13 weeks. However, those positive efficacy signals were tempered by concerns over tolerability, as the trial saw a 28% discontinuation rate among participants receiving the drug due to adverse events. Management's commentary on its upcoming discussions with the FDA and its strategy to mitigate these tolerability issues will be heavily scrutinized.

Beyond obesity, Viking’s other lead asset, VK2809, targets the metabolic liver disease MASH (Metabolic Dysfunction-Associated Steatohepatitis), recently renamed from NASH. The oral drug showed stellar results in its Phase 2b VOYAGE study, with up to 75% of patients achieving MASH resolution without worsening of fibrosis. Despite this success, the company has been awaiting FDA guidance on the design of a Phase 3 program. Any clarity on the regulatory path forward for VK2809 will be a significant catalyst.

The Weight of Expectation in Crowded Markets

Viking's promising pipeline is advancing in some of the most competitive and lucrative therapeutic areas in modern medicine. The obesity market is currently dominated by Eli Lilly's Zepbound and Novo Nordisk's Wegovy, multi-billion-dollar injectable drugs that have set a high bar for efficacy and market penetration. With both giants also pushing forward with oral alternatives, Viking's VK2735 faces immense pressure to differentiate itself not just on efficacy, but also on safety, tolerability, and convenience.

The market dynamics for MASH have also shifted dramatically. Madrigal Pharmaceuticals recently secured the first-ever FDA approval for a MASH treatment with its drug, Rezdiffra. While Viking's VK2809 has demonstrated a potentially best-in-class profile in clinical trials, it will now enter a market with an established competitor rather than breaking entirely new ground. Investors will be looking for management to articulate a clear strategy for how VK2809 can carve out a significant market share in this evolving landscape.

One biotech analyst noted the challenge ahead, stating, "The data for both lead assets is compelling, but execution and market access are everything now. The question is no longer just 'does the drug work?' but 'how does it fit into a treatment paradigm dominated by some of the largest players in the industry?'"

Navigating Biotech's Financial Tides

The ambitious clinical programs come at a significant cost. Viking's R&D expenses have surged, climbing to $90.0 million in the third quarter of 2025, a nearly four-fold increase from the $22.8 million spent in the same period of 2024. This spending spree fueled a net loss of $90.8 million for the quarter. Analysts expect this trend to continue, with the Zacks Consensus Estimate for the fourth quarter pegging the loss at $0.89 per share.

This high cash burn rate makes the company's financial position a critical point of focus. As of September 30, 2025, Viking held $715 million in cash, cash equivalents, and short-term investments. Management has stated this runway is sufficient to fund operations through at least the end of 2026, a period expected to cover key clinical milestones. However, the substantial costs associated with running multiple Phase 3 trials and preparing for potential commercialization mean that the company's long-term funding strategy will be an underlying theme of the upcoming call.

Despite the quarterly losses, which are typical for a pre-revenue biotech, Wall Street sentiment remains overwhelmingly positive. The stock carries a "Strong Buy" consensus from many analysts, with average price targets suggesting a significant upside from its current trading level. This optimism is built on the blockbuster potential of its pipeline. Yet, this bullish outlook is balanced by the inherent risks of drug development, intense competition, and the financial pressures of late-stage research, creating a high-stakes environment as the company heads into its year-end report. The commentary from leadership on February 11 will be pivotal in either reinforcing this confidence or introducing a note of caution for the year ahead.